Genetic Modifiers of Cystic Fibrosis Related Diabetes

Status Enrolling by invitation

Clinical Trial Summary

This research is being done to find the genes and other factors that are responsible for differences among persons with cystic fibrosis. We are particularly interested in the factors that relate to the development of Cystic Fibrosis Related Diabetes (CFRD).

Clinical Trial Description

The study is recruiting people with cystic fibrosis (CF). The medical record is being extracted, and a blood sample is taken for DNA. The DNA samples are tested for variation both at the cystic fibrosis transmembrane conductance regulator (CFTR) gene (the CF gene) and over the entire rest of the genome. Using large numbers of people with CF, and knowing who does and does not have CFRD, we identify genetic variations that associate with CFRD. Knowing these variations allows us to better understand the causes of CFRD, and with enough information, better to predict CFRD and identify people at particularly high or low risk of CFRD. People participating in this study also have the option to participate in related studies of other metabolic traits in CF such as over- and underweight. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01113216
Study type	Observational
Source	Johns Hopkins University
Contact
Status	Enrolling by invitation
Phase
Start date	April 2008
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02703155` - The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes	N/A
Completed	`NCT00763412` - Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis	N/A
Completed	`NCT02398383` - Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes	Early Phase 1
Completed	`NCT02127957` - Effects of an Exercise Program Among CF Patients With Dysglycemia	N/A
Completed	`NCT02039986` - Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
Withdrawn	`NCT00287456` - Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.	N/A
Terminated	`NCT00639626` - Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)	Phase 2/Phase 3
Completed	`NCT00222521` - Insulin Glargine Vs Standard Insulin Therapy	Phase 3
Completed	`NCT00222508` - The Microvascular Complications Study	Phase 3